| ||||||||||||||
|
|
|||||||||||||
lu*
*
Departments of *Anaesthesiology and
Biostatistics, Trakya University Medical Faculty, Edirne, Turkey
Address correspondence and reprint requests to Dr. Alparslan Turan, Trakya University Medical Faculty, Department of Anesthesiology and Reanimation, 22030, Edirne, Turkey. Address e-mail to alparslanturan{at}yahoo.com
In this study we evaluated the analgesic efficacy and the opioid-sparing effect of rofecoxib in ear-nose-throat surgery patients. Patients undergoing nasal septal or sinus surgery were randomized to receive either oral placebo or rofecoxib 50 mg 1 h before surgery. All patients received propofol 0.8 mg/kg, fentanyl 1 µg/kg, and local anesthesia at the operative site. Sedation was maintained by a continuous infusion of propofol adjusted to maintain sedation at a 23 level on the Ramsey scale. Additional fentanyl 0.51 µg/kg was administered at the patients request or if the verbal rating scale score was >4. Patient sedation and pain scores were obtained at 5, 15, 30 45, and 60 min during surgery and 30 min and 2, 4, 6, 12, and 24 h after completion of the procedure. During the postoperative period, diclofenac 75 mg IM was administered for analgesia at the patients request or if the visual analog scale (VAS) rating for pain was more than 4. VAS pain scores, intraoperative fentanyl, and postoperative diclofenac requirements were significantly smaller in the rofecoxib group compared with the placebo group (P < 0.001). The times to first analgesic request were also significantly less in the rofecoxib group. We conclude that the preoperative administration of oral rofecoxib provided a significant analgesic benefit and decreased the need for opioids in patients undergoing nasal septal and nasal sinus surgery.
IMPLICATIONS. The aim of this study was to evaluate the analgesic efficacy and opioid-sparing effect of rofecoxib, a new selective cyclooxygenase-2 inhibitor drug, in ear-nose-throat surgery patients. Preoperative administration of oral rofecoxib provided a significant analgesic benefit and decreased the need for opioids in patients undergoing nasal septal and nasal sinus surgery.
This article has been cited by other articles:
![]() |
A. Turan, P. F. White, B. Karamanlioglu, D. Memis, M. Tasdogan, Z. Pamukcu, and E. Yavuz Gabapentin: An Alternative to the Cyclooxygenase-2 Inhibitors for Perioperative Pain Management Anesth. Analg., January 1, 2006; 102(1): 175 - 181. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. J. Pavlin, E. G. Pavlin, K. D. Horvath, L. B. Amundsen, D. R. Flum, and K. Roesen Perioperative Rofecoxib Plus Local Anesthetic Field Block Diminishes Pain and Recovery Time After Outpatient Inguinal Hernia Repair Anesth. Analg., July 1, 2005; 101(1): 83 - 89. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. F. White Changing Role of COX-2 Inhibitors in the Perioperative Period: Is Parecoxib Really the Answer? Anesth. Analg., May 1, 2005; 100(5): 1306 - 1308. [Full Text] [PDF] |
||||
![]() |
A. Turan, D. Memis, B. Karamanlioglu, R. Yagiz, Z. Pamukcu, and E. Yavuz The Analgesic Effects of Gabapentin in Monitored Anesthesia Care for Ear-Nose-Throat Surgery Anesth. Analg., August 1, 2004; 99(2): 375 - 378. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Ma, J. Tang, P. F. White, A. Zaentz, R. H. Wender, A. Sloninsky, R. Naruse, R. Kariger, R. Quon, D. Wood, et al. Perioperative Rofecoxib Improves Early Recovery After Outpatient Herniorrhaphy Anesth. Analg., April 1, 2004; 98(4): 970 - 975. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Karamanlioglu, A. Turan, D. Memis, and M. Ture Preoperative Oral Rofecoxib Reduces Postoperative Pain and Tramadol Consumption in Patients After Abdominal Hysterectomy Anesth. Analg., April 1, 2004; 98(4): 1039 - 1043. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Buvanendran, J. S. Kroin, K. J. Tuman, T. R. Lubenow, D. Elmofty, M. Moric, and A. G. Rosenberg Effects of Perioperative Administration of a Selective Cyclooxygenase 2 Inhibitor on Pain Management and Recovery of Function After Knee Replacement: A Randomized Controlled Trial JAMA, November 12, 2003; 290(18): 2411 - 2418. [Abstract] [Full Text] [PDF] |
||||
|